



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$49.99
Change (%)	▼ 0.62 (1.23%)
Volume	130,719
52 Week Low	\$29.83
Market Cap	\$2,490,666,367
Rolling EPS	1.32
PE Ratio	38.2222
Shares Outstanding	49,823,292

Data as of 05/25/18 4:02 p.m. ET



Recent Headlines & Events

05/24/18

CEPI Awards \$25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

05/10/18

Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available

05/03/18

Emergent BioSolutions Reports First Quarter 2018 Financial Results

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/24/18	4
05/24/18	4
05/24/18	4
05/24/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows

Vice President,
Investor Relations

Emergent BioSolutions Inc.

Phone: (240) 631 3280

Fax: (240) 413-1917

E-mail: burrowsr@ebsi.com